Business Context and Reporting Period
Company: SeaStar Medical Holding Corporation (ICU)
Filing Type: Form 8-K (Current Report)
Date of Report: August 08, 2025
Reporting Period: The filing reports on events occurring as of August 08, 2025, specifically regarding the resumption of an At-the-Market (ATM) equity offering program.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. Specific capital raise metrics disclosed include:
- ATM Program Status: Resumed sales under an existing ATM Agreement with H.C. Wainwright & Co., LLC.
- Remaining Offering Capacity: Up to an aggregate offering price of $2,166,305.
- Historical Proceeds: As of August 08, 2025, the Company had sold an aggregate of $6.8 million in shares under the ATM Agreement since its inception.
- Previous Suspension: Sales were suspended on July 10, 2025, terminating the continuous offering of the initial $25,000,000 aggregate offering price.
Material Changes
The primary material change reported is the strategic decision to resume equity sales under the ATM Agreement after a brief suspension. The Company previously suspended sales on July 10, 2025, but has now determined to resume sales up to the remaining balance of approximately $2.17 million. No other material changes to operations, debt structure, or liquidity positions are detailed in this specific filing.
Guidance, Outlook, and Management Commentary
- Use of Proceeds: The Company expects to use net proceeds for general corporate purposes, including additions to working capital and capital expenditures. Management retains broad discretion over the specific use of funds.
- Investment Strategy: Until utilized, net proceeds will be invested in investment-grade, interest-bearing securities or held in deposit accounts.
- Offering Terms: There is no minimum offering amount required. The total number of shares to be sold and the final proceeds are not determinable at this time.
- Risks: The filing notes standard securities law restrictions, stating the report does not constitute an offer to sell shares in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current market price of ICU common stock to assess potential dilution from the resumed ATM sales.
- Confirm the exact number of shares sold to date under the ATM program to calculate the weighted average issuance price.
- Review the Company's most recent 10-Q or 10-K to understand current cash reserves and working capital needs, as this filing does not provide current liquidity figures.
- Monitor future 8-K filings for updates on the actual proceeds raised under the resumed $2,166,305 offering capacity.